New 2,3-Benzodiazepine Derivative: Synthesis, Activity on Central Nervous System, and Toxicity Study in Mice

Näytä kaikki kuvailutiedot



Pysyväisosoite

http://hdl.handle.net/10138/333681

Lähdeviite

Amaghnouje, A.; Bohza, S.; Bohdan, N.; Es-Safi, I.; Kyrylchuk, A.; Achour, S.; El Fatemi, H.; Bousta, D.; Grafov, A. New 2,3-Benzodiazepine Derivative: Synthesis, Activity on Central Nervous System, and Toxicity Study in Mice. Pharmaceuticals 2021, 14, 814.

Julkaisun nimi: New 2,3-Benzodiazepine Derivative: Synthesis, Activity on Central Nervous System, and Toxicity Study in Mice
Tekijä: Amaghnouje, Amal; Bohza, Serhii; Bohdan, Nathalie; Es-Safi, Imane; Kyrylchuk, Andrii; Achour, Sanae; El Fatemi, Hinde; Bousta, Dalila; Grafov, Andriy
Julkaisija: Multidisciplinary Digital Publishing Institute
Päiväys: 2021-08-19
URI: http://hdl.handle.net/10138/333681
Tiivistelmä: We report the design and synthesis of a new diazepine derivative, 4-(4-methoxyphenyl)-2,3,4,5-tetrahydro-2,3-benzodiazepin-1-one (VBZ102), and the evaluation of its anxiolytic-like profile, memory impairment effect, and toxicity in Swiss mice. VBZ102 was evaluated for central nervous system effects in an open field, light–dark box, and novel object recognition tests under oral administration for acute and sub-acute treatment. We tested the VBZ102 toxicity in mice through a determination of LD<sub>50</sub> values and examination of the biochemical and histopathological parameters. The VBZ102 induced an anxiolytic effect at different doses both in the light–dark box and open field tests. Unlike other benzodiazepines (e.g., bromazepam), a sedative effect was noted only after administration of the VBZ102 at 10.0 mg/kg.


Tiedostot

Latausmäärä yhteensä: Ladataan...

Tiedosto(t) Koko Formaatti Näytä
pharmaceuticals-14-00814.pdf 5.162MB PDF Avaa tiedosto

Viite kuuluu kokoelmiin:

Näytä kaikki kuvailutiedot